Thoracoscopic lobectomy is a safe and versatile procedure: experience with 500 consecutive patients

Area of Science:

• Thoracic Surgery
• Surgical Oncology
• Pulmonology

Background:

• Thoracoscopic lobectomy presents potential advantages over conventional thoracotomy for early-stage non-small cell lung cancer (NSCLC), including reduced postoperative pain and shorter hospital stays.
• Evaluating outcomes in patients with complex pulmonary conditions is crucial to establish the safety, efficacy, and versatility of this minimally invasive approach.

Purpose of the Study:

• To analyze the safety, efficacy, and versatility of thoracoscopic lobectomy in patients with complex pulmonary conditions.
• To compare outcomes of thoracoscopic lobectomy with conventional thoracotomy for early-stage NSCLC.

Main Methods:

• A prospective database of 500 consecutive patients undergoing thoracoscopic lobectomy from June 1999 to January 2006 was analyzed.
• Demographic, histopathologic, perioperative, and outcome variables were assessed using descriptive statistics and Kaplan-Meier survival analyses.

Main Results:

• Thoracoscopic lobectomy was successfully performed in 492 patients (1.6% conversion rate).
• The cohort included primary NSCLC (83.2%), secondary pulmonary malignancy (7.4%), and benign conditions (9%).
• Overall 2-year survival was 80%, with specific rates for Stage I NSCLC (85%), Stage II+ NSCLC (77%), secondary malignancy (73%), and benign disease (89%). Operative and 30-day mortality were 0% and 1%, respectively.

Conclusions:

• Thoracoscopic lobectomy is a versatile procedure applicable to a wide range of malignant and benign pulmonary diseases.
• The technique is associated with low perioperative morbidity and mortality.
• Survival rates achieved with thoracoscopic lobectomy are comparable to those of traditional thoracotomy.